- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.10. | GSK's investigational antibiotic granted FDA priority review for urinary tract infections | ||
| 18.10. | Stirred becomes first UK health comms agency to achieve EcoVadis Platinum Medal | ||
| 18.10. | Precision, planning and creativity for launch excellence in a volatile sector | ||
| 17.10. | AstraZeneca receives MHRA approval for Wainzua in rare nerve disease ATTRv-PN | ||
| 17.10. | Sanofi and Orano Med partner to advance radioligand therapies for rare cancers | ||
| 17.10. | Amgen shares positive late-stage results for Uplizna in generalised myasthenia gravis | ||
| 17.10. | Women in pharma | ||
| 16.10. | Pfizer's Hympavzi granted FDA approval to treat haemophilia in adult and paediatric patients | ||
| 16.10. | J&J's nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis | ||
| 16.10. | Jazz shares positive results for Zepzelca combination in phase 3 lung cancer study | ||
| 16.10. | Inizio Medical appoints Matt Wadyka as president, US medical affairs | ||
| 15.10. | Eli Lilly's mirikizumab shows promise in phase 3 Crohn's disease study | ||
| 15.10. | Merck and Exelixis partner to evaluate new cancer combination treatments | ||
| 15.10. | FDA advisory committee recommends Stealth's elamipretide for Barth syndrome | ||
| 14.10. | Johnson & Johnson receives updated NICE recommendation for Tecvayli in multiple myeloma | ||
| 14.10. | Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer | ||
| 14.10. | Roche presents two-year data for spinal muscular atrophy treatment Evrysdi in children | ||
| 11.10. | Roche's Itovebi combination granted FDA approval for advanced breast cancer | ||
| 11.10. | Merck and Astellas/Pfizer's bladder cancer combination receives MHRA approval | ||
| 11.10. | Eli Lilly and insitro collaborate to advance new treatments for metabolic diseases | ||
| 10.10. | Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn | ||
| 10.10. | Merck's Keytruda shows promise as perioperative head and neck cancer treatment | ||
| 10.10. | GSK's RSV vaccine Arexvy shown to protect older adults across three seasons | ||
| 10.10. | PM Society Awards 2025 open for entries | ||
| 09.10. | Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
